Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors (nic_physo)

What is the purpose of this trial?

The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for the binding of the radioligand. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the extent of this change will be different than in controls.


Participation Guidelines

Ages: 18 - 60 years

Gender: Both


National Institute on Drug Abuse

Start Date: 09/01/2013

End Date: 03/01/2018

Last Updated: 02/22/2018

Study HIC#: 1210010989

Get Involved

For more information about this study, contact:
Jon Mikael Anderson
+1 203-737-7074
jonmikael.anderson@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image